Abstract

The rice cultivar designated ‘Addi Jo’ and its hybrids and derivatives are disclosed.

IPC Classes  ?

• A01H 6/46 - Gramineae or Poaceae, e.g. ryegrass, rice, wheat or maize
• A01H 5/10 - Seeds

Abstract

Provided herein are green alga Cia8 polypeptides and the polynucleotides that encode them. Also provided herein are transformed cells and transgenic plants that include one or more of the polynucleotides and/or polypeptides provided herein.

IPC Classes  ?

• C07K 14/40 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from fungi from yeasts from Candida
• C07K 14/405 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from algae
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

Provided are thiol-acrylate hydrogels and tunable cell culture materials including thiol-acrylate hydrogels, and methods of making thereof. Also provided are systems for forming three-dimensional cell culture scaffolds including the materials, and methods of culturing cells, including cancer cells, using thiol-acrylate hydrogels and tunable cell culture materials. The materials herein can be used in microfluidic droplet-generating devices.

IPC Classes  ?

• C08G 75/04 - Polythioethers from mercapto compounds or metallic derivatives thereof
• C12N 5/09 - Tumour cells
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

This application relates to new process that utilizes electrodes that incorporate acids that facilitate upgrading of methane and other low molecular weight alkanes to higher order hydrocarbon molecules, such as paraffins, olefins, and aromatics, at temperatures less than 250° C. A primary focus of the invention includes methane conversion to ethylene. The first step of the process includes acid containing electrodes that facilitate the activation of the alkane in the anode layer of the electrochemical reactor. Subsequent steps include the separation of protons from produced longer chain hydrocarbons followed by subsequent electrochemical reduction of the protons to yield hydrogen at the cathode or protons combined with oxygen at the cathode to yield water. The reaction steps in the anode upgrade methane to higher order hydrocarbon products.

IPC Classes  ?

• C25B 3/25 - Reduction
• C25B 9/17 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof
• C25B 1/50 - Processes

Abstract

An energy storage apparatus is described and claimed herein comprising, generally, a battery housing enclosing a negative electrode, a positive electrode, and an electrolyte, wherein the electrolyte comprises a salt dissolved in either an amide-based solvent. In various embodiments, the amide-based solvent is a tertiary amide. Moreover, the energy storage apparatus may be a lithium ion battery that comprises an electrolyte with a lithium salt dissolved in a tertiary amide.

IPC Classes  ?

• H01M 10/0569 - Liquid materials characterised by the solvents
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries

Abstract

Laser ablation devices and methods including laser ablation are provided. The ablation devices can include a deep UV laser. Dual-laser ablation devices are also provided. Biomolecules can be ablated using a combination of deep UV laser and nanoelectrospray, resulting in protonated sample molecules.

IPC Classes  ?

• H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locksArrangements for external adjustment of electron- or ion-optical components
• H01J 49/40 - Time-of-flight spectrometers
• G01N 33/483 - Physical analysis of biological material
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• B23K 26/12 - Working by laser beam, e.g. welding, cutting or boring in a special environment or atmosphere, e.g. in an enclosure
• H01J 49/16 - Ion sourcesIon guns using surface ionisation, e.g. field-, thermionic- or photo-emission
• B23K 26/00 - Working by laser beam, e.g. welding, cutting or boring
• B23K 26/16 - Removal of by-products, e.g. particles or vapours produced during treatment of a workpiece
• H01J 49/00 - Particle spectrometers or separator tubes
• G01N 1/04 - Devices for withdrawing samples in the solid state, e.g. by cutting
• G01N 30/00 - Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography

Abstract

A composition for sealing defects in structural materials such as roads or paved surfaces, the composition preferably comprising one or more shape memory polymer (SMP) components capable of responding to increased temperature by decreasing in volume.

IPC Classes  ?

• C08L 101/12 - Compositions of unspecified macromolecular compounds characterised by physical features, e.g. anisotropy, viscosity or electrical conductivity
• C09J 125/08 - Copolymers of styrene
• C08F 299/02 - Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers from unsaturated polycondensates
• C08L 75/04 - Polyurethanes

Abstract

Asphalt rejuvenating fibers and asphalt rejuvenation materials for self-healing asphalt applications are provided. The asphalt rejuvenating fibers can include a shell surrounding a hollow space. The shell can include alginate salts, an emulsifier, and a plasticizer. The asphalt rejuvenation materials can include the asphalt rejuvenating, an asphalt binder, and aggregate blends.

IPC Classes  ?

• C08L 95/00 - Compositions of bituminous materials, e.g. asphalt, tar or pitch
• C08L 5/04 - Alginic acidDerivatives thereof
• C08L 91/00 - Compositions of oils, fats or waxesCompositions of derivatives thereof
• C08K 5/00 - Use of organic ingredients

Abstract

Provided for are methods of producing triacylglycerol-accumulated microalgae, methods for making bioplastics from triacylglycerol-accumulated microalgae, methods for making alga-mixed plastics, and products including these bioplastics. Methods of triacylglycerol accumulation using centrifugation are also provided. Products such as plastic beads and other consumer products can be made from the bioplastics described herein.

IPC Classes  ?

• C12N 1/12 - Unicellular algaeCulture media therefor
• C12P 7/6463 - Glycerides obtained from glyceride producing microorganisms, e.g. single cell oil
• C08H 99/00 - Subject matter not provided for in other groups of this subclass
• C08L 99/00 - Compositions of natural macromolecular compounds or of derivatives thereof not provided for in groups or
• A01G 33/00 - Cultivation of seaweed

Abstract

2S related disease is one of cancer, cardiovascular disease, acute inflammation, chronic inflammation, and neurological disease.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/275 - NitrilesIsonitriles
• A61K 31/105 - Persulfides
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present disclosure provides for shape memory proppants, methods for making shape memory proppants, and methods of using shape memory proppants, and the like. The strong expandable proppants of the present disclosure may be used in maintaining fracture openings.

IPC Classes  ?

• C09K 8/80 - Compositions for reinforcing fractures, e.g. compositions of proppants used to keep the fractures open
• C09K 8/05 - Aqueous well-drilling compositions containing inorganic compounds only, e.g. mixtures of clay and salt

Abstract

The present disclosure provides for sampling instruments and methods of collecting sample particles. The sampling instrument can include a high-pressure pulsed valve coupled to a gas flow system to displace a sample from a surface. Also included can be a voltage supply coupled to a voltage switch, a suction device, a sample collector, and a collection filter. To collect a sample, extractive particles can be deposited onto a sample present on a substrate. At least a portion of the sample becomes coupled to a portion of the extractive particles to form sample particles. High-pressure gas can be discharged at the sample, thereby aerosolizing a portion of the sample particles to disperse aerosolized sample particles. A portion of the aerosolized sample particles can be collected onto a collection filter to form a collected sample.

IPC Classes  ?

• G01N 1/14 - Suction devices, e.g. pumpsEjector devices
• G01N 1/38 - Diluting, dispersing or mixing samples

Abstract

A method of treating a condition of in a human patient comprising pharmacologically activating a translocator protein of 18 kDa (TSPO), wherein the condition is one of a chronic methamphetamine addiction, a medical consequence of methamphetamine use; a behavioral consequence of methamphetamine use, an HIV associated cognitive motor disorder, an HIV-associated neurodegenerative disorder, and a neuroinflammatory response.

IPC Classes  ?

• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/603 - Salicylic acidDerivatives thereof having further aromatic rings, e.g. diflunisal
• A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone

Abstract

A method of treating cancer or a precancer condition in a mammal comprising administering a therapeutically effective amount of a homovanillyl sinapate analog or pharmacologically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, or a combination thereof.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61P 35/00 - Antineoplastic agents
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/4245 - Oxadiazoles
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof

Abstract

An electroluminescent LED device comprising a hole transport layer, an electron transport layer, an active emissive layer between the hole transport layer and the electron transport layer, and carbon dots forming the active emissive layer.

IPC Classes  ?

• H01L 51/50 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED)
• H05B 45/20 - Controlling the colour of the light
• H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof

Abstract

A variety of hydrophobically modified polypeptoids are provided. The hydrophobically modified polypeptoids can include a polyamide backbone having a random copolymer of two or more different types of repeat units, where one or more of the repeat units have nitrogen atom having a hydrophobic substituent attached thereto. Methods of making the hydrophobically modified polypeptoids are also provided, as well as uses of the hydrophobically modified polypeptoids, for example in liposomal drug delivery.

IPC Classes  ?

• C08G 69/00 - Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A01N 37/18 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N, e.g. carboxylic acid amides or imidesThio-analogues thereof

Abstract

A method of generating one of podocyte progenitor cells and neural stem/progenitor cells comprising the steps of collecting a urine specimen from a patient; centrifuging the urine specimen; and removing the one of podocyte progenitor cells and neural stem/progenitor cells.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/0797 - Stem cellsProgenitor cells
• A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue

Abstract

A load dissipating arthroplasty prosthesis comprising a shell, an articular device extending into the shell through a collar defined in the sell, a head and neck portion of the articular device extending from the collar, a shaft portion of the articular device extending into the shell, and a plurality of shock absorbing arcuate linkers spacing and allowing limited movement between the shell and the articular device.

IPC Classes  ?

• A61F 2/36 - Femoral heads
• A61F 2/34 - Acetabular cups
• A61F 2/30 - Joints

Abstract

Methods for temporary fracture isolation are provided. An existing fracture is treated with a chemical diverter. The chemical diverter is exposed to conditions causing it to expand, plugging the fracture. A new fracture can be created through the application of pressure and fluid, without disrupting the plugged fracture. The chemical diverter can then be removed through biodegradation or the application of a solvent to reopen the first fracture.

IPC Classes  ?

• E21B 43/26 - Methods for stimulating production by forming crevices or fractures
• E21B 33/138 - Plastering the borehole wallInjecting into the formation
• C09K 8/508 - Compositions based on water or polar solvents containing organic compounds macromolecular compounds
• C09K 8/516 - Compositions for plastering borehole walls, i.e. compositions for temporary consolidation of borehole walls characterised by their form or by the form of their components, e.g. encapsulated material
• C09K 8/42 - Compositions for cementing, e.g. for cementing casings into boreholesCompositions for plugging, e.g. for killing wells

Abstract

Products and methods for treating cancer in a human patient comprising administering to the patient therapeutically effective amount of a first pharmaceutically active agent, wherein the first pharmaceutically active agent is one of an isothiocyanatostilbene and a pharmacologically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, or a combination thereof.

IPC Classes  ?

• A61K 31/26 - Cyanate or isocyanate estersThiocyanate or isothiocyanate esters
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids

Abstract

Methods and therapeutics for treating nitric oxide (NO) mediated condition comprising administering a therapeutically effective amount of a pharmaceutical composition containing a therapeutic, wherein the therapeutic one of increases xanthine oxidase (XO) associated nitrite conversion to nitric oxide and increases nitrite conversion to nitric oxide via DADS. Method and devices for measuring an amount of nitrite in a sample comprising obtaining a sample, adding diallyl disulfide (DADS) to the sample, measuring a post DADS amount of nitric oxide (NO) in the sample, and using the post DADS amount of NO in the sample to determine the amount of nitrite in the sample. Methods and therapeutics for diagnosing and treating critical limb ischemia (CLI) versus non-critical limb ischemic peripheral artery disease (PAD) in a patient comprising determining a patient indicator value, where the patient indicator is value one of a total hydrogen sulfide metabolite plasma level, a total nitric oxide, nitrite, and nitrite (NOx) plasma level, a ratio of free hydrogen sulfide plasma level to total NOx plasma level, and a ratio of total hydrogen sulfide metabolite plasma level and total NOx plasma level, diagnosing the patient with as having CLI based on the patient indicator value, and administering to the patient a therapeutic for CLI.

IPC Classes  ?

• A61K 31/105 - Persulfides
• A61K 38/44 - Oxidoreductases (1)
• G01N 33/84 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving inorganic compounds or pH
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients

Abstract

A method is provided for decreasing at least one of the proliferation and the migration of a cancer cell comprising contacting a cancer cell with an effective amount of a pharmaceutically acceptable composition comprising a microRNA (miRNA) having a nucleotide sequence having at least 80% sequence similarity to the nucleotide sequence of miR-3189-3p derived from the miR-3189 mitron of the Growth Differentiation Factor 15 (GDF15) gene. The methods and compositions are advantageous for inhibiting proliferation and migration of, but not limited to, glioblastoma cells, melanoma cells, and breast cancer cells.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters

Abstract

Various embodiments disclosed relate to a method of forming a polypeptide. The method includes contacting a first amino acid-derived N-thiocarboxyanhydrosulfide monomer as a crystalline solid with a polymerization initiator (e.g., in an alkane suspension) to give a polypeptide product. The method further includes contacting the polypeptide product with a second amino acid-derived N-thiocarboxyanhydrosulfide monomer in an alkane suspension.

IPC Classes  ?

• C08G 69/42 - Polyamides containing atoms other than carbon, hydrogen, oxygen, and nitrogen
• C08G 69/00 - Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
• C08G 69/04 - Preparatory processes
• C08G 69/10 - Alpha-amino-carboxylic acids

Abstract

Disclosed are various embodiments for transferring molecules from a surface for mass spectrometry and other sample analysis methods, and the like. A laser is focused onto a tip of an atomic force microscope to remove and capture a quantity of molecules from the surface, so they can be transferred to a mass spectrometer or another instrument for analysis.

IPC Classes  ?

• H01J 49/00 - Particle spectrometers or separator tubes
• G01Q 30/02 - Non-SPM analysing devices, e.g. SEM [Scanning Electron Microscope], spectrometer or optical microscope
• G01Q 60/40 - Conductive probes
• B23K 26/16 - Removal of by-products, e.g. particles or vapours produced during treatment of a workpiece
• H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locksArrangements for external adjustment of electron- or ion-optical components
• H01J 49/40 - Time-of-flight spectrometers

Abstract

A method for one of altering and enhancing the stereospecificity of an enzyme comprising introducing a stereospecific editing domain into the enzyme.

IPC Classes  ?

• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• C12P 21/00 - Preparation of peptides or proteins

Abstract

Described herein are methods of transdifferentiating preadipocytes, populations of transdifferentiated preadipocytes, and methods of using the transdifferentiated preadipocytes.

IPC Classes  ?

• A61K 35/39 - PancreasIslets of Langerhans
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/0793 - Neurons

Abstract

Pneumocystis immune reaction by a recipient subject. The compositions and methods of the disclosure provide advantageous alternatives to available immunogenic determinants for the treatment or prevention of fungal pneumonia.

IPC Classes  ?

• A61K 39/40 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum bacterial
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)

Abstract

A method of generating one of podocyte progenitor cells and neural stem/progenitor cells comprising the steps of collecting a urine specimen from a patient; centrifuging the urine specimen; and removing the one of podocyte progenitor cells and neural stem/progenitor cells.

IPC Classes  ?

• A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/0797 - Stem cellsProgenitor cells

Abstract

A cranial cap dressing for dressing a craniotomy wound comprising a breathable elastic outer layer sized to fit snuggly on a human head of a patient and an absorbent inner layer attached to the breathable elastic outer layer.

IPC Classes  ?

• A61F 13/00 - Bandages or dressingsAbsorbent pads
• A61F 13/12 - Bandages or dressingsAbsorbent pads specially adapted for the head or neck

Abstract

Curcumin conjugates may be used against cancer cells that express the LH receptor: prostate, breast, ovary, testis, uterus, pancreas, and melanoma.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• C07K 7/23 - Luteinising hormone-releasing hormone [LHRH]Related peptides
• A61K 38/24 - Follicle-stimulating hormone [FSH]Chorionic gonadotropins, e.g. HCGLuteinising hormone [LH]Thyroid-stimulating hormone [TSH]
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

−). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.

IPC Classes  ?

• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 9/50 - Microcapsules
• A61K 9/00 - Medicinal preparations characterised by special physical form